1
EXHIBIT 10.1
SCHERING CORPORATION
2000 GALLOPING HILL ROAD KENILWORTH, N.J. 07033
July 27, 2000
Mr. Vaughn M. Kailian, CEO
COR Therapeutics, Inc.
256 East Grand Avenue
South San Francisco, California 94080
Dear Vaughn:
This is with regard to the Collaboration Agreement, dated April 10, 1995, by and
among COR Therapeutics, Inc. ("COR"), and Schering Corporation and
Schering-Plough Ltd. (collectively "Schering"), as amended, (the "Agreement").
In the Second Amendment to the Agreement, dated November 5, 1999, Cor and
Schering agreed to make certain elements of the Second Amendment conditional on
the conduct of a Phase III clinical trial for acute myocardial infarction
("AMI") and have made provision in the Second Amendment for modification of the
Second Amendment based upon the status of such trial as or pre-established
dates, and the Parties desire to modify those dates.
The parties are currently negotiating a Third Amendment to the Agreement to
address this and other issues relating to the Agreement. However, Section X.A of
the Second Amendment provides for the termination of certain provisions of the
Second Amendment in the event that "as of June 30, 2000, the JSC has not voted
to conduct the Phase III Study". Therefore, it is hereby agreed that the
deadline for the decision of the JSC with respect to the conduct of the Phase
III Study is extended until August 31, 2000.
Please indicate COR's acceptance and agreement to the provisions set forth in
this letter by signing below on behalf of COR and returning one signed original
to Schering.
Very truly yours,
Schering Corporation Schering-Plough Ltd.
/s/ David Poorvin /s/ David Poorvin
- ------------------------- -------------------------
David Poorvin David Poorvin
Vice President Prokurist
Acknowledged and Agreed to:
COR Therapeutics, Inc.
By: /s/ Vaughn M. Kailian
-----------------------------
Vaughn M. Kailian
Chief Executive Officer
Dated: 7/28/00
-------------------------